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Abstract
Previous studies on primary biliary cirrhosis (PBC) have focused on the role of T lymphocytes as potential effectors of tissue
injury. We hypothesized that single nucleotide polymorphisms (SNPs) of genes involved in lymphocyte proliferation would be
responsible for uncontrolled expansion of T cells and autoreactivity. To address this, we genotyped DNA from 154 patients
with PBC and 166 ethnically matched healthy controls for SNPs of ﬁve candidate genes (60G/A CTLA-4, 1858 C/T
LYP, -IVS9 C/T foxp3, p1323 C/G ICOS and -9606 T/C CD25) using a TaqMan assay.
We report herein a statistically signiﬁcant decrease in homozygosity rate for the 60A*CTLA-4 allele in patients with PBC
compared to controls (p ¼ 0.0411). Moreover, we found a signiﬁcant association of the same allele and of the LYP*Tallele
with anti-mitochondrial antibody (AMA) serum negativity (p ¼ 0.0304 and 0.0094, respectively). No association between
anyof the other studied SNPs and PBC susceptibility, progression, or AMA statuswas observed. In conclusion, given the high
prevalence of SNPs in CTLA-4 detected in numerous autoimmune diseases, we encourage a more detailed genetic analysis of
this candidate gene. Further, although obtained from a limited number of AMA-negative subjects, our data suggest a potential
genetic heterogeneity for this speciﬁc subgroup of patients with PBC.
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Introduction
Autoimmune diseases recognize a multifactorial
etiopathogenesis (Roitt et al. 1992), most likely
requiring environmental triggers to operate on a
susceptible genetic background. In recent years
intensive work has been performed to elucidate such
genetic predisposition to autoimmune syndromes,
especially following the completion of the human
genome project. Based on the fundamental role of the
major histocompatibility complex (MHC) in antigen
presentation, much effort has been put into the
dissection of its subtypes identifying signiﬁcant and
consistent associationsonly insome cases(Shiinaetal.
2004).Inthiscontext,primarybiliarycirrhosis(PBC),
an autoimmune disease characterized by high-titer
serum anti-mitochondrial autoantibodies (AMA) and
tissueinﬂammationlocalizedtothesmallandmedium-
size intrahepatic bile ducts (Kaplan 1996; Dienes et al.
1997), is interesting because it has no deﬁnite HLA
association (Jones et al. 2003). The study of
autoepitope localization (Van de Water et al. 1995), T
lymphocyte reactivity (Shimoda et al. 1995; Kita et al.
2002), and local tissue reactivity (Yasoshima et al.
1995; Katayanagi et al. 1998) have suggested that the
essential mechanism leading to organ damage is
mediated by T cells (Ludwig et al. 1978; Hashimoto
et al. 1993). We hypothesized that, similar to what
observed in type I diabetes (Pop et al. 2005),
autoimmune thyroid diseases (Setoguchi et al. 2005),
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2004), a primary defect in T cell proliferation would
explaintheexpansionofself-reactiveclonesinPBC.To
investigate this phenomenon, we genotyped a large
population of patients with PBC and healthy controls
for the presence of single nucleotide polymorphisms
(SNPs) of 5 genes involved in T cell expansion. In
particular,westudiedtheprevalenceof60G/ACTLA-
4 (cytotoxic T lymphocyte-associated antigen-4),
1858CT LYP (lymphoid thyrosine phosphatase)
and -IVS9 C/T foxp3 SNPs, all previously associated
with susceptibility to autoimmunity. Moreover, we
studied the p1323 C/G ICOS (Inducible T cell
costimulator) and -9606T/C CD25 SNPs (Table I).
Materials and methods
Study population
After written consent, blood samples from 154
patients with PBC consecutively enrolled at the
Liver Clinic of the San Paolo School of Medicine
(Milan, Italy) were obtained. Clinical characteristics
of the enrolled population are presented in Table II.
In all cases, the diagnosis of PBC was based on
internationally accepted criteria: i.e. presence of
serum AMA at titer higher than 1:40, histological
evidence of liver damage compatible with PBC, and
elevated alkaline phosphatase (.1.5X normal value)
for longer than 6 months (Kaplan 1996). Disease
stage was classiﬁed as early (histological stages I–II) or
advanced (stages III–IV) PBC (Ludwig et al. 1978);
the latter was also deﬁned by a history of major
complications related to portal hypertension. Seventy-
six of 154 patients (49.4%) in our series presented
early disease. Serum AMA testing was performed by
indirect immunoﬂuorescence. A population of 166
age and sex matched healthy subjects, sharing the
same ethnical background as the patients, was used as
control. The protocol corresponded to the guidelines
of the Declaration of Helsinki (Edinburgh, 2000).
DNA extraction and SNP analysis
DNA was extracted from whole blood using a
commercially available kit (Instagene Matrix; Bio-
Rad Laboratories, Segrate, Italy) and stored at 2208C
until used for genotyping. SNP analysis was
performed using TaqMan SNP Assay-on-Demand
for ICOS and CTLA-4 and TaqMan Assay-by-Design
for foxp3, LYP and CD25 (Applied Biosystems.
Foster City, CA); primers were custom designed by
Applied Biosystems (Table I). Polymerase chain
reaction (PCR) ampliﬁcations were performed
according to the manufacturer’s instructions in
10uL reactions, using TaqMan no AmpErase Uni-
versal Mastermix (Applied Biosystems), TaqMan
primers and 5–10ng of sample DNA. The assays
were performed in 96 well PCR plates, each contain-
ing three negative and three genotyping controls. The
PCR protocol included an initial denaturation step at
958C for 10min, 40 cycles of a 15s 928C denaturation
Table I. Primers used for SNP genotyping.
Gene [SNP reference sequence] Primers Sequences
ICOS [rs 4270326] ICOS-F 50-CAACAGGGAGACAATTCCTTCCCCC-30
ICOS-R 50-AAGACATACCTACTAATTAAACTAA-30
Foxp3 [rs 2280883] Foxp3- F 5-GTCAATACACCCCCAACTGGGCACC-3
Foxp3-R 5-TTCCCAACCTTTCCTTGTAACACCC-30
LYP [rs 2476601] LYP-F 50-CCAGCTTCCTCAACCACAATAAATG-30
LYP-R 50-CAACTGCTCCAAGGATAGATGATGA-30
CTLA4 [rs 3087243] CTLA4-F 50-TCTTCACCACTATTTGGGATATAAC-30
CTLA4-R 50-TGGGTTAACACAGACATAGCAGTCC-30
IL2RA/CD25 [rs 1570538] IL2RA-F 50-CCTTAAAGACAGGATCTTGCTCTGT-30
IL2RA-R 50-GAGTTCGAGGCTGCAGTCA-30
Table II. Demographic and clinical features of patients with PBC and controls enrolled in this study.
Patients with PBC Control subjects
Number 154 166
Sex (F/M) 142/12 160/6
Age (years) 66 ^ 56 5 ^ 8
AMA positive 132 (85.7%) –
Advanced disease 78 (50.6%) –
Presence of ascites 13 (8.4%) –
Serum bilirubin (mg/dl) 1.69 ^ 3.379 –
Prothrombin time (INR) 1.04 ^ 0.202 –
Ongoing therapy with ursodeoxycholic acid (UDCA) 130 (84.4%) –
Continuous variables are expressed as mean ^ standard deviation.
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discrimination based on ﬂuorescent quencher analysis
(VIC–FAM) was assessed on a 7900HT Detection
System (Applied Biosystems). Reproducibility of
every set was conﬁrmed by independent re-test of a
randomly chosen subpopulation of samples.
Statistical analysis
Differences in allelic frequencies were assessed by
Fisher’s exact test, followed by calculation of odd
ratios and 95% conﬁdence intervals if statistical
signiﬁcance was detected. Differences in genotype
frequencies among the respective groups were
evaluated by chi square calculation with one degree
of freedom in 3 £ 2 contingency tables. Stratiﬁca-
tion analysis was performed on the cohort to
investigate the effects of sex, disease severity and
antibody status. All analyses were two-tailed and P
values ,0.05 were considered as statistically signiﬁ-
cant. Calculations were performed using GraphPad
Prism software, version 4.0 (GraphPad Software,
Inc., San Diego, CA).
Results
Allelic frequencies obtained in healthy controls in our
study were consistent with previous data for 3 FoxP3,
CTLA-4 and LYP SNPs while SNP frequencies for
ICOS and CD25 were in accordance with GenBank
frequencies. All SNP distributions were in Hardy-
Weinberg equilibrium.
A statistically signiﬁcant difference could be
identiﬁed in the genotypic distribution of the 60G/A
CTLA-4 SNP between patients and controls.
Decreased homozygosity rate of the genomic A allele
was detected in patients with PBC (17.5 vs. 26.7%
in controls, p ¼ 0.0411, Table III) while the GA
and AA genotypes were accordingly associated with
a decreased susceptibility to PBC (OR ¼ 0.4966,
conﬁdence interval 0.2807–0.8784, p ¼ 0.0163).
A concomitant increase in heterozygosity (56.5% in
PBC vs 44.3% in controls) appeared, associated with
no signiﬁcant modiﬁcation in allelic distribution
(p ¼ 0.4760). A signiﬁcant reproduction of the
distribution was linked with AMA positivity
(p ¼ 0.0304). No correlation could be detected with
disease severity.
No differential allelic expression among patients
with PBC and healthy controls was identiﬁed for the
1858C/T LYP SNP, nor could any association with
disease stage be evidenced. However, a correlation
between LYP*Tand serum AMA negativity was found
(OR ¼ 3.619, conﬁdence interval: 1.431–9.153,
p ¼ 0.0094) and conﬁrmed in genotypic distribution
(Table III).
No discrepancies in total allelic frequencies or
genotype distributions (Table III) among patients with
PBC and controls and no divergence in relation to
disease stage or AMA status was noted for -IVS9 C/T
Foxp3, p1323 C/G ICOS and -9606 T/C CD25.
Discussion
In the attempt to identify candidate genes potentially
involved in the lymphocyte dysregulation characteriz-
ing PBC, we genotyped a large population of patients
and controls and detected differences in genotype
Table III. Genotypes distribution in patients with PBC and healthy controls.
PBC
(n=154)
Healthy controls
(n=166)
Total
(n=154)
Early disease
(n=76)
Advanced disease
(n=78)
AMA negative
(n=22)
ICOS GG 5 (3.2%) 3 (2.7%) 0 3 (5%) 0
GC 47 (30.1%) 26 (23.2%) 11 (21.2%) 15 (25%) 3 (16.7%)
CC 104 (66.7%) 83 (74.1%) 41 (78.8%) 42 (70%) 15 (83.3%)
Foxp3 GG 48 (30.6%) 44 (28.8%) 18 (23.7%) 26 (33.8%) 6 (33.3%)
AG 69 (43.3%) 68 (44.4%) 34 (44.7%) 34 (44.2%) 5 (27.8%)
AA 43 (26.1%) 41 (26.8%) 24 (31.2%) 17 (22.1%) 7 (38.9%)
LYP AA 0 1 (0.7%) 0 1 (1.4%) 1 (5.6%)
AG 22 (13.3%) 22 (15.2%) 12 (16%) 10 (14.3%) 5 (27.8%)
GG 143 (86.7%) 121 (83.4%) 63 (84%) 58 (82.9%) 12 (66.7%) *
CTLA4 GG 49 (28.9%) 40 (26%) 21 (27.6%) 19 (24.4%) 4 (18.2%)
AG 72 (44.3%) 87 (56.5%) 43 (56.6%) 44 (56.4%) 16 (72.7%)
AA 45 (26.7%) 27 (17.5%) ** 12 (15.8%) 15 (19.2%) 2 (9.1%) ***
IL2RA/CD25 AA 39 (23.6%) 24 (15.8%) 13 (17.1%) 11 (14.5%) 3 (14.3%)
AG 76 (46.1%) 74 (48.7%) 35 (46.1%) 39 (51.3%) 9 (52.4%)
GG 51 (30.9%) 54 (35.5%) 28 (36.8%) 26 (34.2%) 7 (33.3%)
Patients with PBC are also stratiﬁed according to disease stage and serum AMA status.
*P ¼ 0.0022, X
2 ¼ 12.231 AMA negative vs. healthy controls; **P ¼ 0.0411, X
2 ¼ 6.384 PBC vs. healthy controls. ***P ¼ 0.0304,
X
2 ¼ 6.984 AMA negative vs. healthy controls.
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patients and controls and for the CTLA-4 and LYP
SNPs depending on the AMA status. Interestingly,
CTLA-4 is a key inhibitor of uncontrolled T
lymphocyte proliferation, fundamental for the main-
tenance of peripheral tolerance. Its transcript presents
a vast number of SNPs, tied by variable degrees of
linkage (Kristiansen et al. 2000). In particular, the 30-
UTR -60G/A SNP has been associated with suscep-
tibility to SLE (Barreto et al. 2004; Torres et al. 2004),
multiple sclerosis (Suppiah et al. 2005), and celiac
disease (Hunt et al. 2005), either isolated or in
association with linkage markers (Zhernakova et al.
2005). Moreover, Ueda et al. (2003) demonstrated
that the association of the 260 A allele in linkage
equilibrium with another genetic polymorphism, the
CTLA-4* þ 49A allele correlated with the production
of the soluble (s) form of the receptor. S-CTLA-4
appears to have a direct regulatory function, binding
in a competitive manner to the common ligands of
CTLA-4 and CD28, B7-1 and B7-2, thus inhibiting
proliferation by CD28 stimulation. Due to linkage
patterns, the susceptibility allele G can be identiﬁed in
healthy and affected individuals, making a complete
linkage analysis of the region necessary for further
elucidation. Encouraged by previous ﬁndings of
CTLA-4 SNP association in PBC (Agarwal et al.
2000), we analyzed the -60G/A SNP conﬁrming the
pattern of celiac disease (Hunt et al. 2005), i.e. a
decrease in homozygosity of the protective A allele,
but we could not detect a concomitant increase in
homozygosity of the putative susceptibility allele. The
small subpopulation of AMA negative patients also
resembles this genotype distribution. These appar-
ently controversial results could be explained either by
the limited size of the cohort or the previously
described linkage pattern occurring in the region.
Given the difﬁculty in recruiting extended cohorts of
patients for rare diseases and ideally genetically
homogeneous controls (Tsuneyama et al. 1998), a
future analysis would have to focus on detailed
sequencing and microsatellite dissection of the area,
to allow a clariﬁcation of the genetic relevance of
CTLA-4 to PBC. Issues correlated with cohort size
also apply to the small subpopulation of patients with
AMA-negative PBC, namely 5–10% of affected
individuals (Miyakawa et al. 2001; Talwalkar et al.
2003). We are aware that the statistical power of the
present comparisons and the obtained data might be
questionable, mainly due to the difﬁculty in recruiting
a sufﬁcient number of subjects in this subgroup.
Nonetheless, our ﬁndings on 1858T*LYP are intri-
guing, since this regulatory gene could be related to T
to B lymphocyte interactions and autoantibody
production. The polymorphic 1858T*LYP allele
interferes with the binding of the negative regulatory
kinase Csk to the activatory kinase LYP, thus
deregulating the intracellular cascade and leading to
lymphocyte expansion (Bottini et al. 2004). The
polymorphism at position 1858 has been associated
with autoimmune diseases (Hinks et al. 2005; Viken
et al. 2005) but not to primary sclerosing cholangitis
(PSC) (Viken et al. 2005), an autoimmune chronic
cholestatic liver disease sharing several features with
PBC but targeting also the large bile ducts (Wiesner
et al. 1985). We could not identify a different
distribution between PBC cases and healthy controls,
but detected a signiﬁcant association with AMA
negativity.
Finally, neither an association with prevalence of
PBC, nor correlation with disease severity or antibody
status could be identiﬁed with any of the other
analyzed SNPs. Considering the demonstrated
expression of B7 by biliary epithelia (Tsuneyama
et al. 1998), the potential role of ICOS, one of its
natural ligands, warrants further investigation. More-
over, interesting data on the differential expression of
T regulatory cells in autoimmune liver diseases
(Longhi et al. 2004) drew our attention to CD25
and foxp3. Nonetheless, we could not identify any
association with SNPs in both genes, thus preventing
us from conﬁrming a recent report on the expression
of foxp3 in PBC (Park et al. 2005).
In conclusion, we have identiﬁed other possible
candidate genes that might explain, at least in part,
PBC onset and progression. The recent development
of platforms allowing high-throughput analysis of a
large number of SNPs at once (Syvanen 2005) may
offer in the near future solid preliminary data to guide
the selection of candidate polymorphisms for future
studies on large series of patients and controls.
References
Agarwal K, Jones DE, et al. 2000. CTLA-4 gene polymorphism
confers susceptibility to primary biliary cirrhosis. J Hepatol
32:538–541.
Barreto M, Santos E, et al. 2004. Evidence for CTLA4 as a
susceptibility gene for systemic lupus erythematosus. Eur J Hum
Genet 12:620–626.
Bottini N, Musumeci L, et al. 2004. A functional variant of
lymphoid tyrosine phosphatase is associated with type I diabetes.
Nat Genet 36:337–338.
Dienes HP, Lohse AW, et al. 1997. Bile duct epithelia as target cells
in primary biliary cirrhosis and primary sclerosing cholangitis.
Virchows Arch 431:119–124.
Hashimoto E, Lindor KD, et al. 1993. Immunohistochemical
characterization of hepatic lymphocytes in primary biliary
cirrhosis in comparison with primary sclerosing cholangitis and
autoimmune chronic active hepatitis. Mayo Clin Proc
68:1049–1055.
Hinks A, Barton A, et al. 2005. Association between the PTPN22
gene and rheumatoid arthritis and juvenile idiopathic arthritis in
a UK population: Further support that PTPN22 is an
autoimmunity gene. Arthritis Rheum 52:1694–1699.
Hunt KA, McGovern DP, et al. 2005. A common CTLA4
haplotype associated with coeliac disease. Eur J Hum Genet
13:440–444.
S. Oertelt et al. 262Jones DE, Donaldson PT. 2003. Genetic factors in the pathogenesis
of primary biliary cirrhosis. Clin Liver Dis 7:841–864.
Kaplan MM. 1996. Primary biliary cirrhosis. N Engl J Med
335:1570–1580.
Katayanagi K, Kono N, et al. 1998. Isolation, culture and
characterization of biliary epithelial cells from different
anatomical levels of the intrahepatic and extrahepatic biliary
tree from a mouse. Liver 18:90–98.
Kita H, Lian ZX, et al. 2002. Identiﬁcation of HLA-A2-restricted
CD8(+) cytotoxic T cell responses in primary biliary cirrhosis:
T cell activation is augmented by immune complexes cross-
presented by dendritic cells. J Exp Med 195:113–123.
Kristiansen OP, Larsen ZM, et al. 2000. CTLA-4 in autoimmune
diseases—a general susceptibility gene to autoimmunity? Genes
Immun 1:170–184.
Liu MF, Wang CR, et al. 2004. Decreased CD4+CD25+T cells in
peripheral blood of patients with systemic lupus erythematosus.
Scand J Immunol 59:198–202.
Longhi MS, Ma Y, et al. 2004. Impairment of CD4(+)CD25(+)
regulatory T-cells in autoimmune liver disease. J Hepatol
41:31–37.
Ludwig J, Dickson ER, et al. 1978. staging of chronic
nonsuppurative destructive cholangitis (syndrome of primary
biliary cirrhosis). Virchows Arch A Pathol Anat Histol
379:103–112.
Miyakawa H, Tanaka A, et al. 2001. Detection of antimitochondrial
autoantibodies in immunoﬂuorescent AMA-negative patients
with primary biliary cirrhosis using recombinant autoantigens.
Hepatology 34:243–248.
Park O, Grishina I, et al. 2005. Analysis of the foxp3/Scurﬁn gene in
Crohn’s Disease. NY Acad Sci, 1051:218.
Pop SM, Wong CP, et al. 2005. Single cell analysis shows decreasing
FoxP3 and TGFbeta1 coexpressing CD4+CD25+ regulatory T
cells during autoimmune diabetes. J Exp Med 201:1333–1346.
Roitt IM, Hutchings PR, et al. 1992. The forces driving
autoimmune disease. J Autoimmun 5:11–26.
Setoguchi R, Hori S, et al. 2005. Homeostatic maintenance of
natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by
interleukin (IL)-2 and induction of autoimmune disease by IL-2
neutralization. J Exp Med 201:723–735.
Shiina T, Inok H, et al. 2004. An update of the HLA genomic
region, locus information and disease associations: 2004. Tissue
Antigens 64:631–649.
Shimoda S, Nakamura M, et al. 1995. HLA DRB4 0101-restricted
immunodominant T cell autoepitope of pyruvate dehydrogenase
complex in primary biliary cirrhosis: Evidence of molecular
mimicry in human autoimmune diseases. J Exp Med 181:
1835–1845.
Suppiah V, Alloza I, et al. 2005. The CTLA4+49 A/G*G-CT60*G
haplotype is associated with susceptibility to multiple sclerosis in
Flanders. J Neuroimmunol 164:148–153.
Syvanen AC. 2005. Toward genome-wide SNP genotyping. Nat
Genet 37:S5–10.
Talwalkar JA, Souto E, et al. 2003. Natural history of pruritus
in primary biliary cirrhosis. Clin Gastroenterol Hepatol
1:297–302.
Torres B, Aguilar F, et al. 2004. Association of the CT60 marker of
the CTLA4 gene with systemic lupus erythematosus. Arthritis
Rheum 50:2211–2215.
Tsuneyama K, Harada K, et al. 1998. Expression of co-stimulatory
factor B7-2 on the intrahepatic bile ducts in primary biliary
cirrhosis and primary sclerosing cholangitis: An immunohisto-
chemical study. J Pathol 186:126–130.
Ueda H, Howson JM, et al. 2003. Association of the T-cell
regulatory gene CTLA4 with susceptibility to autoimmune
disease. Nature 423:506–511.
Van de Water J, Ansari A, et al. 1995. Heterogeneity of autoreactive
T cell clones speciﬁc for the E2 component of the pyruvate
dehydrogenase complex in primary biliary cirrhosis. J Exp Med
181:723–733.
Viken MK, Amundsen SS, et al. 2005. Association analysis of the
1858C . T polymorphism in the PTPN22 gene in juvenile
idiopathic arthritis and other autoimmune diseases. Genes
Immun 6:271–273.
Wiesner RH, LaRusso NF, et al. 1985. Comparison of the
clinicopathologic features of primary sclerosing cholangitis and
primary biliary cirrhosis. Gastroenterology 88:108–114.
Yasoshima M, Nakanuma Y, et al. 1995. Immunohistochemical
analysis of adhesion molecules in the micro-environment of
portal tracts in relation to aberrant expression of PDC-E2 and
HLA-DR on the bile ducts in primary biliary cirrhosis. J Pathol
175:319–325.
Zhernakova A, Eerligh P, et al. 2005. CTLA4 is differentially
associated with autoimmune diseases in the Dutch population.
Hum Genet :1–9.
SNP analysis of genes 263